Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience

Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrucci, Silvia, Casazza, Giovanni, Angileri, Luisa, Tavecchio, Simona, Germiniasi, Francesca, Berti, Emilio, Marzano, Angelo Valerio, Genovese, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141229/
https://www.ncbi.nlm.nih.gov/pubmed/32183179
http://dx.doi.org/10.3390/jcm9030791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141229/
https://www.ncbi.nlm.nih.gov/pubmed/32183179
http://dx.doi.org/10.3390/jcm9030791

Ejemplares similares